

Tim M Illidge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8708859/publications.pdf>

Version: 2024-02-01

215
papers

14,502
citations

29994

54
h-index

22102

113
g-index

218
all docs

218
docs citations

218
times ranked

15486
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. <i>Nature Reviews Immunology</i> , 2022, 22, 124-138.	10.6	81
2	Guidelines for the management of mature T-cell and natural killer-cell lymphomas (excluding cutaneous). <i>Journal of Clinical Oncology</i> , 2022, 40, 196, 507-522.	1.2	12
3	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2203-2212.	0.8	10
4	Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries. <i>Cancers</i> , 2022, 14, 145.	1.7	7
5	Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?. <i>Cancers</i> , 2021, 13, 457.	1.7	27
6	4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , 2021, 22, 332-340.	5.1	51
7	Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. <i>Clinical Cancer Research</i> , 2021, 27, 4353-4366.	3.2	27
8	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3591-3601.	0.8	21
9	Progress and pitfalls with the use of image-guided personalised approaches in lymphoma. <i>British Journal of Radiology</i> , 2021, 94, 20210609.	1.0	3
10	TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, S411.	0.2	0
11	Lymphoma: advances in imaging and radiotherapy – introductory editorial. <i>British Journal of Radiology</i> , 2021, 94, 20219005.	1.0	2
12	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021, 138, 135-135.	0.6	2
13	Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?. <i>British Journal of Haematology</i> , 2020, 191, 13-14.	1.2	1
14	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4091-4101.	2.5	33
15	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. <i>Radiation Oncology</i> , 2020, 15, 254.	1.2	62
16	Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 27-37.	0.4	22
17	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. <i>Blood</i> , 2020, 135, 1829-1832.	0.6	78
18	The investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 363-381.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 909-933.	0.4	67
20	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
21	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 203-206.	2.5	15
22	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. <i>Cancers</i> , 2020, 12, 2835.	1.7	8
23	Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. <i>Future Oncology</i> , 2019, 15, 4223-4234.	1.1	8
24	Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. <i>EJNMMI Research</i> , 2019, 9, 18.	1.1	9
25	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1732-1741.	0.8	38
26	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. <i>International Reviews of Immunology</i> , 2019, 38, 79-91.	1.5	3
27	Immunogenic Effects of Radiotherapy for Bladder Cancer. <i>Clinical Oncology</i> , 2019, 31, e26.	0.6	0
28	CLINICAL OUTCOMES ASSOCIATED WITH THE TREATMENT OF NEWLY DIAGNOSED STAGE IV CLASSICAL HODGKIN LYMPHOMA IN PRACTICE SETTINGS IN FRANCE, GERMANY AND THE UNITED KINGDOM. <i>Hematological Oncology</i> , 2019, 37, 488-490.	0.8	0
29	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. <i>British Journal of Dermatology</i> , 2019, 180, 496-526.	1.4	111
30	The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2019, 185, 402-409.	1.2	15
31	Clinical Development of Novel Drug-Radiotherapy Combinations. <i>Clinical Cancer Research</i> , 2019, 25, 1455-1461.	3.2	42
32	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	6.3	517
33	Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. <i>British Journal of Haematology</i> , 2019, 184, 202-214.	1.2	35
34	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018, 131, 2120-2124.	0.6	56
35	Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial. <i>Clinical Oncology</i> , 2018, 30, 201-203.	0.6	6
36	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1100-1118.	0.4	46

#	ARTICLE	IF	CITATIONS
37	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 652-669.	0.4	71
38	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <i>Annals of Oncology</i> , 2018, 29, 301-310.	0.6	98
39	Recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018, 29, 1069-1070.	0.6	2
40	Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. <i>Leukemia and Lymphoma</i> , 2018, 59, 1413-1419.	0.6	16
41	The anti-PD-1 era "an opportunity to enhance radiotherapy for patients with bladder cancer. <i>Nature Reviews Urology</i> , 2018, 15, 251-259.	1.9	27
42	A novel approach to low dose total skin electron beam therapy (TSEBT). <i>European Journal of Cancer</i> , 2018, 101, S31.	1.3	0
43	How do we move towards a personalised approach in the treatment of Early Hodgkin lymphoma?. <i>British Journal of Haematology</i> , 2018, 182, 163-164.	1.2	1
44	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018, 29, iv19-iv29.	0.6	243
45	Revisiting the role of radiotherapy in Hodgkin lymphoma to augment systemic immunity. <i>Leukemia and Lymphoma</i> , 2018, 59, 2519-2520.	0.6	0
46	LYMRIT 37-01: A Phase I/II Study of ¹⁷⁷ Lu-Lilotomab Satetraxetan (Betalutin [®]) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) "Analysis with 6-Month Follow-up. <i>Blood</i> , 2018, 132, 2879-2879.	0.6	11
47	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018, 132, 997-997.	0.6	3
48	Immune Checkpoint Inhibitors in Lung Cancer "An Unheralded Opportunity?. <i>Clinical Oncology</i> , 2017, 29, 207-217.	0.6	6
49	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. <i>Leukemia</i> , 2017, 31, 1611-1621.	3.3	37
50	Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2017, 23, 5514-5526.	3.2	282
51	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017, 130, 2709-2717.	0.6	176
52	Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. <i>European Journal of Haematology</i> , 2017, 99, 553-558.	1.1	16
53	Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment. <i>EMBO Molecular Medicine</i> , 2017, 9, 1646-1659.	3.3	12
54	The influence of radiation in the context of developing combination immunotherapies in cancer. , 2017, 5, 115-122.	1.4	12

#	ARTICLE	IF	CITATIONS
55	Harmonization of programmed cell death ligand-1 diagnostic assays in non-small cell lung cancer. <i>Translational Cancer Research</i> , 2017, 6, S553-S556.	0.4	1
56	Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. <i>Oncotarget</i> , 2016, 7, 17035-17046.	0.8	25
57	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a <scp>UK</scp> National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016, 173, 274-282.	1.2	12
58	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016, 27, v91-v102.	0.6	102
59	Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. <i>Journal of Clinical Oncology</i> , 2016, 34, 1443-1447.	0.8	31
60	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2016, 57, 1269-1280.	0.6	4
61	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. <i>Clinical Oncology</i> , 2016, 28, 726-731.	0.6	10
62	Guidelines for the management of diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016, 174, 43-56.	1.2	125
63	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. <i>British Journal of Radiology</i> , 2016, 89, 20160472.	1.0	32
64	Immunotherapy with radiotherapy in urological malignancies. <i>Current Opinion in Urology</i> , 2016, 26, 514-522.	0.9	5
65	Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. <i>Cancer Immunology Research</i> , 2016, 4, 621-630.	1.6	50
66	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 627-642.	12.5	230
67	¹⁷⁷ Lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. <i>Blood</i> , 2016, 128, 1780-1780.	0.6	2
68	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016, 128, 2993-2993.	0.6	5
69	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016, 128, 4144-4144.	0.6	9
70	Abstract SY31-02: The interplay of radiotherapy with the tumour microenvironment: Novel opportunities to overcome adaptive resistance. , 2016, , .		0
71	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. <i>Cancer Treatment Reviews</i> , 2015, 41, 503-510.	3.4	482
72	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 144-152.	0.4	18

#	ARTICLE	IF	CITATIONS
73	Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 32-39.	0.4	150
74	Personalised approach to treating early Hodgkin's lymphoma. BMJ, The, 2015, 350, h2927-h2927.	3.0	2
75	Modern Radiation Therapy for Extranodal Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2015, 92, 11-31.	0.4	303
76	Immuno-regulatory antibodies for the treatment of cancer. Expert Opinion on Biological Therapy, 2015, 15, 787-801.	1.4	40
77	Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 372, 1598-1607.	13.9	619
78	PET-Directed Therapy for Hodgkin's Lymphoma. New England Journal of Medicine, 2015, 373, 392-392.	13.9	16
79	Obinutuzumab in hematologic malignancies: Lessons learned to date. Cancer Treatment Reviews, 2015, 41, 784-792.	3.4	52
80	The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. Oncoimmunology, 2015, 4, e1016709.	2.1	78
81	Balancing Risks in Developing a Personalised Approach to the Treatment of Early Hodgkin Lymphoma: Have We Got the Balance Right?. Clinical Oncology, 2015, 27, 454-456.	0.6	0
82	Turning Radiotherapy into an Effective Systemic Anti-cancer Treatment in Combination with Immunotherapy. Clinical Oncology, 2015, 27, 696-699.	0.6	11
83	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Leukemia and Lymphoma, 2015, 56, 703-710.	0.6	29
84	Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. Blood, 2015, 126, 1537-1537.	0.6	5
85	Brentuximab Vedotin in Combination with Chp in Patients (Pts) with Newly-Diagnosed Cd30+ Peripheral T-Cell Lymphomas (Ptcl): 2-Year Follow-Up. Annals of Oncology, 2014, 25, iv327.	0.6	0
86	Phase 3 Trial of Brentuximab Vedotin and Chp Versus Chop in the Frontline Treatment of Patients (Pts) with Cd30+ Mature T-Cell Lymphomas (Mtcl). Annals of Oncology, 2014, 25, iv338.	0.6	0
87	Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology, 2014, 3, e955691.	2.1	686
88	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Tj ETQq0 0 0 rgBT/Overlook 10 Tf 50		
89	New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor. Leukemia and Lymphoma, 2014, 55, 3-4.	0.6	1
90	Risk of Premature Menopause After Treatment for Hodgkin's Lymphoma. Journal of the National Cancer Institute, 2014, 106, .	3.0	48

#	ARTICLE	IF	CITATIONS
91	Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 164, 39-52.	1.2	27
92	Comment on: "Clinical Features, Management, and Prognosis of an International Series of 161 Patients With Limited-Stage Diffuse Large B-Cell Lymphoma of the Bone (the IELSG14 Study)". <i>Oncologist</i> , 2014, 19, 91289-1289.		1
93	Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30 ⁺ Peripheral T-Cell Lymphomas: Results of a Phase I Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 3137-3143.	0.8	153
94	4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. <i>Lancet Oncology</i> , 2014, 15, 457-463.	5.1	191
95	Emerging Opportunities for the Combination of Molecularly Targeted Drugs with Radiotherapy. <i>Clinical Oncology</i> , 2014, 26, 266-276.	0.6	12
96	A novel systemically administered toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. <i>International Journal of Cancer</i> , 2014, 135, 820-829.	2.3	41
97	Update on obinutuzumab in the treatment of B-cell malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 1507-1517.	1.4	18
98	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, iii70-iii75.	0.6	257
99	Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. <i>Cancer Research</i> , 2014, 74, 5458-5468.	0.4	1,014
100	Fractionated ⁹⁰ Y-ibritumomab Tiuxetan Radioimmunotherapy As an Initial Therapy of Follicular Lymphoma: An International Phase II Study in Patients Requiring Treatment According to GELF/BNLI Criteria. <i>Journal of Clinical Oncology</i> , 2014, 32, 212-218.	0.8	57
101	Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, S776.	0.4	11
102	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma: Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 49-58.	0.4	259
103	Modern Radiation Therapy for Hodgkin Lymphoma: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 854-862.	0.4	479
104	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014, 124, 3095-3095.	0.6	14
105	Abstract 5034: The antitumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. , 2014, , .		2
106	Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. <i>Leukemia and Lymphoma</i> , 2013, 54, 2008-2015.	0.6	11
107	Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. <i>Blood</i> , 2013, 121, 251-259.	0.6	130
108	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013, 168, 192-200.	1.4	81

#	ARTICLE	IF	CITATIONS
109	Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. <i>Cell Death and Differentiation</i> , 2013, 20, 765-773.	5.0	18
110	Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2013, 54, 2531-2533.	0.6	120
111	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. <i>British Journal of Cancer</i> , 2013, 108, 2399-2406.	2.9	49
112	The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. <i>British Journal of Haematology</i> , 2013, 162, 842-845.	1.2	19
113	XVII. Radiotherapy in early stage Hodgkin lymphoma. <i>Hematological Oncology</i> , 2013, 31, 92-95.	0.8	4
114	Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. <i>British Journal of Cancer</i> , 2013, 109, 2566-2573.	2.9	35
115	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <i>British Journal of Cancer</i> , 2013, 109, 2560-2565.	2.9	8
116	Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. <i>Onc Immunology</i> , 2013, 2, e24501.	2.1	4
117	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <i>Haematologica</i> , 2013, 98, 611-614.	1.7	88
118	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2013, 122, 1809-1809.	0.6	24
119	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. <i>Blood</i> , 2013, 122, 4386-4386.	0.6	6
120	Radiotherapy physics research in the UK: challenges and proposed solutions. <i>British Journal of Radiology</i> , 2012, 85, 1354-1362.	1.0	11
121	Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012, , 99.	1.2	0
122	Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. <i>Blood</i> , 2012, 119, 3523-3533.	0.6	106
123	Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2190-2196.	0.8	890
124	Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 543-545.	1.4	16
125	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012, 159, 541-564.	1.2	127
126	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 446-467.	1.2	58

#	ARTICLE	IF	CITATIONS
127	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. Blood, 2012, 120, 2745-2745.	0.6	6
128	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. Blood, 2012, 120, 3701-3701.	0.6	7
129	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. Blood, 2012, 120, 60-60.	0.6	32
130	New antibody drug treatments for lymphoma. Expert Opinion on Biological Therapy, 2011, 11, 623-640.	1.4	15
131	Radioimmunotherapy in follicular lymphoma. Best Practice and Research in Clinical Haematology, 2011, 24, 279-293.	0.7	29
132	Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. Radiotherapy and Oncology, 2011, 100, 86-92.	0.3	309
133	Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood, 2011, 117, 4519-4529.	0.6	270
134	The future of anti-CD20 monoclonal antibodies: are we making progress?. Blood, 2011, 117, 2993-3001.	0.6	117
135	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. British Journal of Cancer, 2011, 104, 719-725.	2.9	48
136	Current Developments in Specialty Training. Clinical Oncology, 2011, 23, 431-433.	0.6	1
137	X. When should radiotherapy be used in lymphoma?. Annals of Oncology, 2011, 22, iv57-iv60.	0.6	1
138	YY1 expression predicts favourable outcome in follicular lymphoma. Journal of Clinical Pathology, 2011, 64, 125-129.	1.0	33
139	Tumor cell embryonality and the ploidy number 32n: Is it a developmental checkpoint?. Cell Cycle, 2011, 10, 1873-1874.	1.3	9
140	Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. British Journal of Cancer, 2011, 105, 628-639.	2.9	140
141	Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab. Blood, 2011, 118, 1644-1644.	0.6	9
142	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. Blood, 2011, 118, 3091-3091.	0.6	6
143	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. Blood, 2011, 118, 443-443.	0.6	11
144	Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species. Blood, 2011, 118, 1651-1651.	0.6	0

#	ARTICLE	IF	CITATIONS
145	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. <i>Blood</i> , 2010, 116, 3373-3374.	0.6	8
146	New insights into the mechanisms of action of radioimmunotherapy in lymphoma. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 987-998.	1.2	4
147	Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. <i>Journal of Immunological Methods</i> , 2010, 360, 30-38.	0.6	25
148	Radiotherapy Research Priorities for the UK. <i>Clinical Oncology</i> , 2010, 22, 707-709.	0.6	8
149	Radioimmunotherapy of Lymphoma: A Treatment Approach Ahead of Its Time or Past Its Sell-By Date?. <i>Journal of Clinical Oncology</i> , 2010, 28, 2944-2946.	0.8	34
150	A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies. <i>Clinical Radiology</i> , 2010, 65, 720-728.	0.5	9
151	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010, 116, 961-961.	0.6	13
152	Anti-HLA-DR Monoclonal Antibody Evokes a Novel Non-Apoptotic Cell Death Pathway In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3245-3245.	0.6	0
153	Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2124.	0.1	0
154	Radioimmunotherapy: Strategies for the future in indolent and aggressive lymphoma. <i>Current Oncology Reports</i> , 2009, 11, 363-370.	1.8	4
155	Phase 1/2 study of fractionated 131-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009, 113, 1412-1421.	0.6	79
156	When is a predose a dose too much?. <i>Blood</i> , 2009, 113, 6034-6035.	0.6	4
157	Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. <i>Journal of Clinical Investigation</i> , 2009, 119, 2143-59.	3.9	149
158	New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 725-725.	0.6	5
159	Abstract C184: Validation of an ELISA for the determination of Rituximab pharmacokinetics in clinical trials subjects. , 2009, , .		0
160	Endopolyploidy in irradiated p53-deficient tumour cell lines: Persistence of cell division activity in giant cells expressing Aurora-B kinase. <i>Cell Biology International</i> , 2008, 32, 1044-1056.	1.4	69
161	How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1263-1273.	0.6	9
162	Consensus conference: Implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice – Report of a European workshop. <i>European Journal of Cancer</i> , 2008, 44, 366-373.	1.3	25

#	ARTICLE	IF	CITATIONS
163	Radiation Therapy with Tositumomab (B1) Anti-CD20 Monoclonal Antibody Initiates Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase-Dependent Cell Death that Overcomes Resistance to Apoptosis. <i>Clinical Cancer Research</i> , 2008, 14, 4925-4934.	3.2	31
164	Current treatment approaches for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008, 49, 663-676.	0.6	20
165	Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. <i>Blood</i> , 2008, 111, 4764-4770.	0.6	84
166	Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies. <i>Blood</i> , 2008, 112, 883-883.	0.6	1
167	A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma. <i>Blood</i> , 2008, 112, 4828-4828.	0.6	0
168	Microscopic Intratumoral Dosimetry of Radiolabeled Antibodies Is a Critical Determinant of Successful Radioimmunotherapy in B-Cell Lymphoma. <i>Cancer Research</i> , 2007, 67, 1335-1343.	0.4	10
169	Fusion of Metabolic Function and Morphology: Sequential [18F]Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Studies Yield New Insights Into the Natural History of Bone Metastases in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 3440-3447.	0.8	159
170	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. <i>Blood</i> , 2007, 109, 4655-4662.	0.6	200
171	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007, 110, 54-58.	0.6	171
172	Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration.. <i>Blood</i> , 2007, 110, 359-359.	0.6	1
173	A50 iodogen labelling method preserves immunoreactivity of high specific activity 131I-labelled rituximab for clinical RIT. <i>Nuclear Medicine Communications</i> , 2006, 27, 293-294.	0.5	1
174	A21 The microscopic tumour biodistribution of 131I-labelled mAb is critical in predicting successful radioimmunotherapy of lymphoma. <i>Nuclear Medicine Communications</i> , 2006, 27, 286.	0.5	0
175	Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. <i>BMC Cancer</i> , 2006, 6, 6.	1.1	84
176	Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma. <i>Cancer</i> , 2006, 107, 686-695.	2.0	35
177	Macrophage Depletion Can Enhance Combined Radiation and Anti-CD40 Monoclonal Antibody Therapy of B-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 2501-2501.	0.6	0
178	Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation.. <i>Blood</i> , 2006, 108, 2508-2508.	0.6	0
179	Anti-CD40: Janus or gatekeeper?. <i>Blood</i> , 2005, 106, 2595-2596.	0.6	1
180	Segregation of genomes in polyploid tumour cells following mitotic catastrophe. <i>Cell Biology International</i> , 2005, 29, 1005-1011.	1.4	98

#	ARTICLE	IF	CITATIONS
181	What's new in the management of cutaneous T-cell lymphoma?. <i>Clinical Oncology</i> , 2005, 17, 174-184.	0.6	13
182	Cyclophosphamide Inhibition of Anti-CD40 Monoclonal Antibody-Based Therapy of B Cell Lymphoma Is Dependent on CD11b+ Cells. <i>Cancer Research</i> , 2005, 65, 7493-7501.	0.4	9
183	Anti-CD40 monoclonal antibody. <i>Leukemia and Lymphoma</i> , 2005, 46, 1105-1113.	0.6	24
184	Neurocognitive Function and Progression in Patients With Brain Metastases Treated With Whole-Brain Radiation and Motexafin Gadolinium: Results of a Randomized Phase III Trial. <i>Journal of Clinical Oncology</i> , 2004, 22, 157-165.	0.8	523
185	Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004, 125, 294-317.	1.2	134
186	Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. <i>Blood</i> , 2004, 103, 1485-1494.	0.6	21
187	Apparent modulation of CD20 by rituximab: an alternative explanation. <i>Blood</i> , 2004, 103, 3989-3991.	0.6	21
188	A new anti-idiotypic antibody capable of binding rituximab on the surface of lymphoma cells. <i>Blood</i> , 2004, 104, 2540-2542.	0.6	44
189	Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2004, 104, 131-131.	0.6	2
190	Cyclophosphamide Induced CD11b+ Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.. <i>Blood</i> , 2004, 104, 3280-3280.	0.6	0
191	Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. <i>Journal of Cell Science</i> , 2003, 116, 4095-4106.	1.2	94
192	Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. <i>Blood</i> , 2003, 102, 1449-1457.	0.6	81
193	Nuclear envelope-limited chromatin sheets are part of mitotic death. <i>Histochemistry and Cell Biology</i> , 2002, 117, 243-255.	0.8	31
194	Motexafin gadolinium prolongs time to neurologic progression in lung cancer patients with brain metastases: results of a randomized phase III trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 92.	0.4	1
195	Predictors of survival for patients with brain metastases: results of a randomized phase III trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 54, 93.	0.4	1
196	Cervical Neuropathy Following Mantle Radiotherapy. <i>Clinical Oncology</i> , 2002, 14, 468-471.	0.6	13
197	Impairment of neurocognitive function in brain metastases patients: baseline results from the phase III trial with motexafin gadolinium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 135-136.	0.4	2
198	Most troublesome quality of life concerns in patients with brain metastases: baseline results from the phase III trial with motexafin gadolinium. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 410.	0.4	0

#	ARTICLE	IF	CITATIONS
199	Trastuzumab: Designer Drug or Fashionable Fad?. <i>Clinical Oncology</i> , 2001, 13, 427-433.	0.6	1
200	Antibody therapy of lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2001, 2, 953-961.	0.9	13
201	Hypercalcaemia, Parathyroid Hormone-Related Protein and Malignancy. <i>Clinical Oncology</i> , 2001, 13, 372-377.	0.6	2
202	RELEASE OF MITOTIC DESCENDANTS BY GIANT CELLS FROM IRRADIATED BURKITT'S LYMPHOMA CELL LINES. <i>Cell Biology International</i> , 2000, 24, 635-648.	1.4	107
203	The Emerging Role Of Radioimmunotherapy In Haematological Malignancies. <i>British Journal of Haematology</i> , 2000, 108, 679-688.	1.2	29
204	A New in Vivo and in Vitro B cell Lymphoma Model, $\bar{\bar{t}}$ -BCL1. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000, 15, 571-580.	0.7	15
205	Radioimmunotherapy in the $\bar{\bar{t}}$ -BCL1B cell Lymphoma Model: Efficacy Depends on More Than Targeted Irradiation Alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000, 15, 581-591.	0.7	10
206	POLYPLOID GIANT CELLS PROVIDE A SURVIVAL MECHANISM FOR p53 MUTANT CELLS AFTER DNA DAMAGE. <i>Cell Biology International</i> , 2000, 24, 621-633.	1.4	147
207	Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy. <i>Current Pharmaceutical Design</i> , 2000, 6, 1399-1418.	0.9	26
208	The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma. <i>Blood</i> , 1999, 94, 233-243.	0.6	27
209	The Junior Radiology Forum: What do the trainees think about the future of oncology training?. <i>Clinical Oncology</i> , 1998, 10, 71-72.	0.6	2
210	The future of oncology training: From the trainees' perspective. <i>Clinical Oncology</i> , 1998, 10, 84-91.	0.6	6
211	Radiation-induced apoptosis. <i>Clinical Oncology</i> , 1998, 10, 3-13.	0.6	15
212	Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. <i>Clinical Oncology</i> , 1996, 8, 257-258.	0.6	62
213	Arthritis and carcinoma.. <i>Annals of the Rheumatic Diseases</i> , 1993, 52, 86-86.	0.5	5
214	Euthanasia.. <i>BMJ: British Medical Journal</i> , 1992, 305, 1225-1225.	2.4	1
215	Effect of dihydroxy-bile salts on the interaction of trypsin and trypsin inhibitors. <i>Biochemical Society Transactions</i> , 1988, 16, 168-168.	1.6	0